Alvimopan monohydrate (ADL 8-2698 monohydrate) is a potent, selective, orally active and reversible μ-opioid receptor antagonist, with an IC 50 of 1.7 nM. Alvimopan monohydrate has selectivity for μ-opioid receptor (K i =0.47 nM) over κ- and δ-opioid receptors (K i s=100, 12 nM, respectively). Alvimopan monohydrate can be used for the research of postoperative ileus.
性状
Solid
IC50 & Target[1][2]
IC50: 1.7 nM (μ-opioid receptor)
体外研究(In Vitro)
Alvimopan inhibits the loperamide-stimulated [S]GTPγS binding to membranes containing the cloned human μ-opioid receptor, with an IC50 of 1.7 nM. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
Alvimopan (0.1-1.0 mg/kg; p.o.) partially antagonizes the slowing of small intestinal transit of Sn-labelled microspheres produced by morphine in rats.
Alvimopan (3 mg/kg; p.o.) has no effect on the visceromotor behavioural responses (VMR) induced by noxious colorectal distension (CRD) in conscious rats. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
ClinicalTrial
参考文献
[1]. Bourdonnec BL, et, al. Novel trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidines as mu opioid receptor antagonists with improved opioid receptor selectivity profiles. Bioorg Med Chem Lett. 2008 Mar 15;18(6):2006-12.[2]. Erowele GI, et, al. Alvimopan (Entereg), a Peripherally Acting mu-Opioid Receptor Antagonist For Postoperative Ileus. P T. 2008 Oct;33(10):574-83.